Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 19/20 | 0.60 |
| ▸ | MAPK8 | P45983 | 6/20 | 0.54 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.52 |
| ▸ | GRK5 | P34947 | 2/20 | 0.51 |
| ▸ | GRK2 | P25098 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2203243 | 0.81 | IGF1R (0.38) | IGF1R | |
| SCHEMBL12429556 | 0.81 | IGF1R (0.60) | IGF1RMAPK8GRK5GRK2 | |
| SCHEMBL3690348 | 0.78 | ABCB1 (0.37) | IGF1R | |
| SCHEMBL12429622 | 0.75 | IGF1R (1.00) | IGF1RMAPK8MAPK10 | |
| SCHEMBL12429610 | 0.74 | IGF1R (0.87) | IGF1RMAPK8MAPK10GRK5GRK2 | |
| SCHEMBL12429491 | 0.74 | IGF1R (0.78) | IGF1RMAPK8GRK5GRK2 | |
| SCHEMBL12429608 | 0.74 | IGF1R (0.78) | IGF1RMAPK8MAPK10GRK5GRK2 | |
| SCHEMBL12429611 | 0.73 | IGF1R (0.82) | IGF1RMAPK8MAPK10GRK5GRK2 | |
| SCHEMBL12429624 | 0.72 | IGF1R (0.82) | IGF1RMAPK8MAPK10 | |
| SCHEMBL12429541 | 0.72 | IGF1R (0.84) | IGF1RMAPK8MAPK10GRK5GRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7981903-B2 | 2-[2-{phenylamino}-1H-pyrrolo[2,3-D]pyrimidin-4-yl)amino] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer | GLAXOSMITHKLINE LLC (US) | 2011-07-19 | — | — | US | disclosed |
| US-7981903-B2 | 2-[2-{phenylamino}-1H-pyrrolo[2,3-D]pyrimidin-4-yl)amino] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer | GLAXOSMITHKLINE LLC (US) | 2011-07-19 | — | — | US | disclosed |
| US-20100204196-A1 | 2-[2--1H-Pyrrolo[2,3-D]Pyrimidin-4-YL)Amino] Benzamide Derivatives As IGF-1R Inhibitors For The Treatment Of Cancer | GLAXOSMITHKLINE LLC | 2010-08-12 | — | — | US | disclosed |
| US-20100204196-A1 | 2-[2--1H-Pyrrolo[2,3-D]Pyrimidin-4-YL)Amino] Benzamide Derivatives As IGF-1R Inhibitors For The Treatment Of Cancer | GLAXOSMITHKLINE LLC | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204196-A1 | 2-[2--1H-Pyrrolo[2,3-D]Pyrimidin-4-YL)Amino] Benzamide Derivatives As IGF-1R Inhibitors For The Treatment Of Cancer | IGF1R, IGFBP2, IGFBP1 | IGF1R 1/4885MAPK8 1305/4885MAPK10 1958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.